MorphoSys: A European Champion Crossing The Biopharma Rubicon
Insight Into Europe's Maturing Biopharma Market
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
You may also be interested in...
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
More Encouraging Real World Data From UK – But Can It Turn Around European Sentiment On AZ COVID-19 Vaccine?
Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AZ shot matching it on cutting hospitalizations.
UK’s Real-World Data Shows Value Of Initial COVID Vaccines Doses – But Can It Shift Policy Elsewhere?
Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AstraZeneca shot matching it on cutting hospitalizations.